Prognostic Value of Early Postoperative Troponin T in Patients Undergoing Coronary Artery Bypass Grafting. by Gahl, Brigitta et al.
Prognostic Value of Early Postoperative Troponin T in Patients
Undergoing Coronary Artery Bypass Grafting
Brigitta Gahl, MSc; Volkhard G€ober, MD; Ayodele Odutayo, MD, PhD; Hendrik T. Tevaearai Stahel, MD; Bruno R. da Costa, PhD;
Stephan M. Jakob, MD; G. Martin Fiedler, MD; Olivia Chan, MSc; Thierry P. Carrel, MD; Peter J€uni, MD
Background-—Cardiac troponin T (cTnT) is elevated after coronary artery bypass grafting surgery. The aim of this study was to
determine the association between cTnT elevations between 6 and 12 hours after coronary artery bypass grafting and in-hospital
outcome.
Methods and Results-—We prospectively studied 1722 patients undergoing isolated coronary artery bypass grafting. We assessed
the association between conventional cTnT (749 patients) and high-sensitivity cTnT (hs-cTnT; 973 patients) 6 to 12 hours
postoperatively with in-hospital major adverse cardiac or cerebrovascular events (MACCE), a composite of all-cause death,
myocardial infarction, or stroke. The prespeciﬁed secondary outcome was a safety composite of MACCE, resuscitation, intensive
care unit readmission or admission ≥48 hours, inotrope or vasopressor use ≥24 hours, or new-onset renal insufﬁciency. Among
patients with a conventional cTnT measurement, 92 experienced a MACCE (12%) and 146 experienced a safety composite event
(19%). Likewise, for hs-cTnT, 114 experienced a MACCE (12%) and 153 experienced a safety composite event (16%). Compared
with cTnT ≤200 ng/L, each 200-ng/L increment in cTnT was associated with a monotonous increase in the odds of MACCE and
the safety composite outcome. Conventional and hs-cTnT demonstrated moderate discrimination for MACCE (areas under the
ﬁtted receiver operating characteristics curve, 0.72 and 0.77 for conventional and hs-cTnT, respectively) and the safety composite
outcome (areas under the ﬁtted receiver operating characteristics curve, 0.66 and 0.74 for conventional and hs-cTnT, respectively)
and resulted in improved prognostic performance when added to the EuroSCORE. At a cutoff of 800 ng/L, conventional and
hs-cTnT provided clinically relevant power to rule in MACCE and the safety composite outcome.
Conclusions-—cTnT levels assessed between 6 and 12 hours after coronary artery bypass grafting identify patients at increased
risk of MACCE or other complications. ( J Am Heart Assoc. 2018;7:e007743. DOI: 10.1161/JAHA.117.007743.)
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C oronary artery bypass grafting (CABG) surgery is anestablished revascularization strategy for adults with
multivessel coronary artery disease. However, patients who
undergo CABG may develop periprocedural complications,
such as myocardial infarction (MI), cardiogenic shock, stroke,
acute kidney injury, and others. Early identiﬁcation of
complications after CABG is important to allow quick
therapeutic strategies, such as emergent reexploration of
grafts, immediate coronary angiography with or without
percutaneous intervention, insertion of intra-aortic balloon
pump, and additional monitoring in the intensive care unit.
Cardiac troponin is unsurprisingly elevated after CABG and
may be a consequence of insufﬁcient myocardial protection or
myocardial ischemia related to inadequate reperfusion.1–3
Therefore, it remains unclear how to interpret changes of
troponin values in the postoperative setting and whether
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troponin elevations have a prognostic value for in-hospital
complications after CABG. Existing studies on the association
between troponin elevations after CABG and in-hospital
complications also have important limitations.4–7 First, inves-
tigators have examined adults undergoing all cardiac surgical
procedures as opposed to limiting their analysis to CABG.
Because the magnitude of postoperative troponin elevation
varies according to the cardiac surgical procedure,5 the
clinical applicability of these studies to adults undergoing
isolated CABG is limited.4–6 Second, few studies focused on
troponin elevations measured earlier than 24 hours,4,7 and
the window of opportunity to meaningfully improve a patient’s
postoperative prognosis may have closed after the ﬁrst
postoperative day. Earlier postoperative assessment of
troponin is, therefore, necessary to improve the clinical
management of patients undergoing CABG. To our knowledge,
only 3 small studies have assessed the association between
troponin measurements taken at ≤12 hours postoperatively
and subsequent in-hospital complications. In the ﬁrst study,
troponin I (TnI) was measured immediately after CABG in 540
adults and, if elevated, was associated with a 17-fold increase
in perioperative MI or death.8 In the second study, troponin T
measured between 8 and 16 hours postoperatively had
moderate to high discrimination (area under the curve,
≥0.73) for perioperative MI.9 The third study was a pilot
study conducted by our group.10 Among 290 adults under-
going isolated CABG, we demonstrated that a cardiac troponin
T (cTnT) increase of 1000 ng/L, measured at a mean
8.1 hours postoperatively, was associated with a 7-fold
increase in in-hospital complications, including periprocedural
MI, prolonged need for vasopressors, and new-onset renal
insufﬁciency. We also reported that a cutoff of 800 ng/L is
useful to identify patients at risk for subsequent complica-
tions. Although presurgical risk scores, such as the Euro-
SCORE, show some association with postsurgical outcomes,
this is moderate at best. It would be desirable to have a
marker assessed early in the postoperative course with a
more pronounced association with postoperative course of
patients that could be used for clinical decision making.
In this prospective cohort study, we wanted to determine
the association between cTnT levels measured 6 to 12 hours
after CABG and in-hospital outcome, validating our previous
ﬁndings, including the prespeciﬁed cutoff of 800 ng/L,10 and
further investigate the clinical utility of early cTnT.
Methods
Patient Population
Using a prospectively maintained institutional registry (Intellect
1.7; Dendrite Clinical Systems, Henley-on-Thames, UK), we
identiﬁed all consecutive patients undergoing isolated CABG at
the University Hospital of Bern (Bern, Switzerland) from
October 17, 2006 (when cTnT assays were introduced at our
laboratory), to December 31, 2013. The study population was
limited to adults with at least 1 troponin measurement between
6 and 12 hours after surgery. Patients who underwent CABG
from January 1, 2008, to December 31, 2008, were analyzed as
part of a previously published development cohort10 and were
excluded. One of us (B.G.) had full access to all the data in the
study and takes responsibility for its integrity and the data
analysis. The data, analytic methods, and study materials will
not be made available to other researchers for purposes of
reproducing the results or replicating the procedure.
At our institution, isolated CABG procedures are performed
almost exclusively with minimal extracorporeal circulation
(MECC). Patients undergoing procedures that used standard
ECC (extracorporeal circulation), those undergoing beating
heart surgery, and those who required a concomitant
procedure on the carotid artery were excluded to achieve a
homogeneous study population. Also, patients with a recent
MI occurring <7 days before their CABG procedure were
excluded to avoid elevated cTnT levels before surgery. The
study was approved by the local research ethics committee
(Kantonale Ethikkommission Bern) in accordance with the
Declaration of Helsinki. All patients provided written informed
consent.
Clinical Perspective
What Is New?
• Early postoperative cardiac troponin T (cTnT), assessed 6 to
12 hours postoperatively in patients who had undergone
coronary artery bypass grafting, demonstrated moderate
discrimination for major adverse cardiac or cerebrovascular
events and a safety composite outcome.
• A cutoff value of 800 ng/L for conventional cTnT and high-
sensitivity cTnT provided clinically relevant power to rule in
major adverse cardiac or cerebrovascular events and the
safety composite outcome: patients with early conventional
cTnT and hs-cTnT levels >800 ng/L were 7 to 12 times
more likely to subsequently experience a major adverse
cardiac or cerebrovascular event or safety event in the
hospital compared with patients with lower early cTnT
levels.
What Are the Clinical Implications?
• Conventional and hs-cTnT levels after coronary artery
bypass grafting are clinically useful in identifying patients
at increased risk of complications.
• Early cTnT elevations may allow for the emergent investi-
gation and management of postoperative complications,
which could have the potential to improve postoperative
outcomes.
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Clinical Procedures
Details of thesurgical procedureandanesthesiawerepreviously
described in detail.10 Brieﬂy, all procedures were performed via
full sternotomy using MECC with moderate systemic hypother-
mia (32°C) with the MECC system (Jostra, Hirlingen, Germany)
and a single-shot low-volume cardioplegia (100 mL Cardio-
plexol; LaboratoriumDr G. Bichsel AG, Unterseen, Switzerland).
If necessary, a second dose of 50 to 100 mL was administered
after 45 to 60 minutes of cross-clamp time. Cardiac arrest
characteristically occurred within 5 to 8 seconds. The left
internal mammary artery, the left radialis artery, and/or a
segment of the great saphenous vein were typically used as
bypass conduits. The anesthetic protocol was standardized and
included the use of fentanyl, midazolam, and isoﬂurane.
Assessments for Biomarkers
To qualify for this study, patients had to have at least 1 cTnT
assessment available between 6 and 12 hours postopera-
tively. Routine postoperative assessments of cTnT, creatine
kinase (CK), and the muscle-brain type CK (CK-MB; mass)
were scheduled at 9 and 18 hours postoperatively, as
calculated from the time point of completion of suture. If
multiple assessments were available within the eligible time
window, the value assessed closest to 9 hours was used for
analysis. Patients without cTnT assessments within this
window were excluded from the analysis.
Conventional cTnT was introduced at our laboratory on
October 17, 2006, and replaced by a high-sensitivity cTnT
(hs-cTnT) assay on August 1, 2010. Both conventional and
hs-cTnT assays were measured using an electrochemolumi-
nescent enzyme immunoassay on a Modular analytics E170
platform (Roche Diagnostics, Mannheim, Germany). The 99th
percentile cutoff point is 10 ng/L for the conventional cTnT
assay and 14 ng/L for the hs-cTnT assay. CK-MB (mass)
levels were measured on the same platform, and CK levels
were measured using a UV test on a Roche Modular P800
(Roche Diagnostics).
Prognostic Variables
The prespeciﬁed primary prognostic variable was cTnT,
assessed between 6 and 12 hours postoperatively. The
secondary prognostic variables were the logistic version of
the European System for Cardiac Operative Risk Evaluation
(subsequently referred to as EuroSCORE) and requirement for
inotropes or vasopressors within 6 hours postoperatively, as
previously reported.10 For each patient, we calculated the
EuroSCORE, which predicts the risk of 30-day all-cause
mortality from preoperative factors on the basis of a logistic
regression model using age, sex, comorbid conditions, patient
history, and left ventricular ejection fraction.11
Clinical Outcomes
The prespeciﬁed primary outcome was in-hospital major
adverse cardiac or cerebrovascular event (MACCE), deﬁned as
a composite of death from any cause, MI, or stroke. The
prespeciﬁed secondary outcome was a safety composite of
MACCE, resuscitation, stay at the intensive care unit of
>48 hours’ duration, readmission to the intensive care unit,
need for inotropes or vasopressors for >24 hours, or new-
onset renal insufﬁciency, as previously reported for the
analysis of the development cohort.10 The diagnosis of MI was
based on signs or symptoms consistent with myocardial
ischemia, ECG changes, and CK and CK-MB (mass) levels, as
speciﬁed by the Academic Research Consortium for the
adjudication of events occurring after CABG.12 For periproce-
dural events occurring <72 hours after CABG, MI was
assumed if CK-MB (mass) or CK levels increased to >10
times the upper reference limit; or if CK-MB (mass) or CK
levels increased to >5 times the upper reference limit and
new pathologic Q waves were observed in ≥2 contiguous ECG
leads or recurrent signs or symptoms consistent with MI were
observed. Postoperative echocardiography was performed to
detect hypokinesia or akinesia only when considered clinically
indicated. Events compatible with the occurrence of an MI
were retrospectively adjudicated independently by a senior
cardiologist (V.G.) who was unaware of observed cTnT levels
while evaluating the imaging records. Stroke was deﬁned as
episode of neurological dysfunction caused by a focal cerebral
infarction, with subsequent conﬁrmation by imaging.13 New-
onset renal insufﬁciency was deﬁned as a new need for
dialysis or, in patients with preoperative creatinine levels
<2 mg/dL (<172 lmol/L), an increase in postoperative
creatinine levels >2 mg/dL and at least twice the preoper-
ative value.14
Statistical Analysis
We conducted 2 main analyses. First, we assessed the
prognostic performance of cTnT measured at 6 to 12 hours
for predicting our study outcomes, with additional consider-
ation of the EuroSCORE and the need for inotropes or
vasopressors. Second, we sought to validate our previously
identiﬁed cutoff of 800 ng/L for cTnT.10 All analyses were
performed separately for conventional cTnT and hs-cTnT.
For the primary prognostic variable, cTnT levels, we
determined the crude association with study outcomes by
ﬁrst calculating odds ratios (ORs) for prespeciﬁed categories
of cTnT of >200 to 400, >400 to 600, >600 to 800, >800 to
1200, and >1200 ng/L compared with the reference category
of patients with cTnT of ≤200 ng/L. We performed a
nonparametric test for trend among the ORs for the cTnT
categories. We then used logistic regression to model the
association between log cTnT values and the logit of the
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primary or secondary outcome, and we back-transformed the
resulting logits to probabilities and plotted them against cTnT
values. The kernel density estimates of the distribution and
quarters of cTnT values were superimposed on the graph to
allow simultaneous presentation of the distribution of cTnT
values in the studied population and their association with the
risk of a future primary or secondary outcome event. We also
examined univariable associations between the secondary
prognostic variables and study outcomes. The need for
inotropes or vasopressors within 6 hours postoperatively was
included in regression models as a binary prognostic variable.
To ensure that ORs for EuroSCORE were directly comparable
with those calculated for binary variables, we expressed the
ORs for EuroSCORE per 2 SD change15 after logarithmic
transformation to correct for the skewed distribution of the
data. We also included all prognostic variables (log cTnT, need
for inotropes or vasopressors, and EuroSCORE) in a single
multivariable model to assess their association with study
outcomes. We did not include additional prognostic variables
because our intention was to examine the role of cTnT as a
marker of underlying risk of poor in-hospital outcomes.
To evaluate the prognostic performance of the 3 prognos-
tic variables in our study, we assessed area under the ﬁtted
receiver operating characteristics curve (AUC) using a
maximum likelihood logistic regression model. We also
assessed the corresponding integrated discrimination
improvement using the EuroSCORE as a reference. The
integrated discrimination improvement reﬂects the gain of
prognostic performance when adding need for inotropes or
vasopressors, log cTnT levels, or both to the reference
model.16 We then used linear regression to determine the
association between the logit of the speciﬁcities and log cTnT
to correctly identify patients without subsequent clinical
outcome using a piecewise linear function for log cTnT
estimated from linear splines, with 8 knots equally distributed
over the range of available log cTnT levels. Using the ﬁtted
receiver operating characteristic curve of sensitivity against
1-speciﬁcity of cTnT levels, we then derived likelihood ratios
for positive (LR+) and negative tests (LR). The LR+ quantiﬁes
how much more likely it is to ﬁnd a cTnT value at least as high
as a given cutoff in patients with the outcome (sensitivity)
compared with patients without the outcome (1-speciﬁcity). A
test can be considered to provide clinically relevant power to
rule in the outcome if the LR+ is >5. The LR indicates how
much less likely it is to ﬁnd a lower cTnT than a given cutoff
(ie, a negative test result) in patients with the outcome (1-
sensitivity) compared with patients without (speciﬁcity); LR
can be considered to have a clinically relevant power to rule
out the outcome if it is <0.2. Crude 292 tables, ﬁtted
sensitivity, speciﬁcity, LR+, LR, and posttest probability after
a positive test result were then reported for 200-ng/L
increments of cTnT from 200 to 1400 ng/L. To facilitate the
clinical translation of our work, we constructed nomograms to
allow clinicians to derive posttest probabilities of the primary
and secondary outcomes in our study as a function of
assumed pretest probabilities and cTnT values. This was done
by multiplying the corresponding pretest odds of clinical
outcomes with the LR+ and LR found for different cTnT
values to derive posttest odds of clinical outcomes. The
posttest odds were then back-transformed into a posttest
probability.
Finally, we used logistic regression to examine the
association between an early postoperative cTnT level of
>800 ng/L and MACCE, the safety composite outcome, and
individual components of each outcome. To assess calibra-
tion, we compared the probabilities of MACCE and safety
composite below and above the prespeciﬁed cutoff of
800 ng/L cTnT in the development cohort10 with risks
observed below and above the cutoff in the validation cohort,
and we compared observed risks of MACCE and safety
composite below and above the cutoff with predicted
probabilities for cTnT and hs-cTnT in the validation cohort.
Because MI was likely to drive the association between cTnT
levels and the safety composite outcome, we conducted a
sensitivity analysis to determine whether the association
between postoperative cTnT levels of >800 ng/L and the
safety composite outcome would be maintained after exclu-
sion of MI from the composite outcome deﬁnition. Patient and
procedural characteristics were presented as numbers with
percentage, meanSD, or median with interquartile range
(IQR), as appropriate. All P values and 95% conﬁdence
intervals (CIs) are 2 sided. All calculations were performed
using Stata 12 (StataCorp, College Station, TX) and R
(https://www.r-project.org).
Results
General Characteristics of the Study Cohort
Between October 17, 2006, and December 31, 2013, 2922
consecutive patients underwent isolated CABG surgery at our
hospital and 2096 met our inclusion criteria, of whom 75 had
to be excluded because cTnT was not measured in the
prespeciﬁed time window suitable for our study (Figure 1). A
further 299 of 2021 patients, who underwent isolated CABG
between January 1, 2008, and December 31, 2008, were
excluded because they were already previously examined as
part of the development cohort.10 The remaining 1722
patients represent the validation cohort and were included
in the current analysis.
A total of 749 patients underwent cTnT testing with the
conventional assay, and 973 patients underwent cTnT testing
with the high-sensitivity assay at a median of 8.8 hours (IQR,
8.2–9.3 hours) and 8.7 hours (IQR, 8.1–9.2 hours)
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postoperatively, respectively. The median conventional cTnT
was 180 ng/L (IQR, 110–300 ng/L; range, 19–4300 ng/L)
and the median hs-cTnT was 320 ng/L (IQR, 220–470 ng/L;
range, 54–6010 ng/L). Among adults who received a con-
ventional cTnT test, 92 experienced a MACCE (12%) and 146
experienced a safety composite event (19%). Likewise, among
adults who received an hs-cTnT test, 114 experienced a
MACCE (12%) and 153 experienced a safety composite event
(16%). All MIs occurred within 72 hours after CABG.
Overall, the mean age of study participants was 66 years
(Table 1). A total of 332 participants were women (19%), 563
had diabetes mellitus (33%), 452 had a history of MI (26%),
and 372 had left main coronary disease (22%). A total of 335
participants (19%) were classiﬁed as having New York Heart
Association stage III or IV heart failure. With respect to
procedural characteristics, the mean duration of operation
was 205 minutes, the mean ECC time was 70 minutes, and
the mean cross-clamp time was 44 minutes. Additional
Excluded (n=2249)
Combined with other types of cardiac or aortic surgery 
(n=1423)
Combined with carotid surgery (n=31)
MIs <8 days before surgery (n=683)
Off pump CABG (n=25)
Standard extracorporeal circulation (n=87)
2021 included
Validation cohort (n=1722)
Conventional cTnT (n=749)
High sensitivity cTnT (n=973)
Development cohort (n=299*)
Conventional cTnT (n=299)
Eligible patients with isolated CABG (n=2096)
Excluded (n=75)
No cTnT measurement available in time window (n=75)    
Intraoperative death (n=3) 
Logistic reasons (n=72)
Consecutive patients undergoing CABG 
(n=4345)
Figure 1. Patient ﬂow. The asterisk indicates that 9 patients who underwent coronary artery bypass
grafting (CABG) between January 1, 2008, and December 31, 2008, were originally excluded from the
development cohort because they had received an ablation or a closure of a patent foramen ovale;
therefore, previously published results are based on only 290 analyzed patients.10 cTnT indicates cardiac
troponin T; and MI, myocardial infarction.
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Table 1. Patient and Procedural Characteristics Stratiﬁed by Type of cTnT
Characteristics
All Patients Conventional cTnT hs-cTnT
(N=1722) (n=749) (n=973)
Patient characteristics
Age, y 66.09.6 66.09.7 66.09.5
Female sex 332 (19) 154 (21) 178 (18)
Body mass index, kg/m2 27.84.5 27.64.4 27.94.5
Diabetes mellitus 563 (33) 252 (34) 311 (32)
Current smoker 399 (23) 185 (25) 214 (22)
Hypertension 1390 (81) 595 (79) 795 (82)
Positive cardiovascular
family history
554 (32) 264 (35) 290 (30)
Most recent myocardial infarction
Any history of myocardial infarction 452 (26) 212 (28) 240 (25)
Preoperative, d
8–21 106 (6) 57 (8) 49 (5)
22–90 69 (4) 39 (5) 30 (3)
>90 277 (16) 116 (15) 161 (17)
Previous CABG* 31 (2) 13 (2) 18 (2)
Previous stroke 127 (7) 43 (6) 84 (9)
Extracardiac arteriopathy 376 (22) 138 (18) 238 (24)
Chronic obstructive pulmonary disease 193 (11) 87 (12) 106 (11)
Dialysis 18 (1) 5 (1) 13 (1)
Last preoperative creatinine, lmol/L 80 (69–93) 80 (69–92) 81 (70–94)
Creatinine clearance, mL/min 85.831.5 83.431.8 87.731.2
Sinus rhythm 71 (4) 18 (2) 53 (5)
No. of diseased vessels
1 32 (2) 17 (2) 15 (2)
2 242 (14) 129 (17) 113 (12)
3 1426 (83) 593 (79) 833 (86)
Left main coronary disease 372 (22) 148 (20) 224 (23)
Ejection fraction, % 57.412.1 56.612.6 58.111.6
CCS III or IV 611 (35) 290 (39) 321 (33)
NYHA III or IV 335 (19) 125 (17) 210 (22)
Urgency
Emergency 51 (3) 24 (3) 27 (3)
Urgent 267 (16) 133 (18) 134 (14)
Logistic EuroSCORE 2.6 (1.5–4.6) 2.7 (1.5–4.8) 2.5 (1.5–4.5)
Procedural characteristics
Duration of operation, min 204.647.0 194.245.2 212.746.8
ECC time, min 70 (56–85) 68 (55–82) 71 (57–86)
Cross-clamp time, min 44 (35–54) 43 (34–54) 44 (35–55)
Values are arithmetic meanSD, number (percentage), or median (interquartile range). CABG indicates coronary artery bypass grafting; CCS, Canadian Cardiovascular Society; cTnT,
cardiac troponin T; ECC, extracorporeal circulation; hs-cTnT, high-sensitivity cTnT; and NYHA, New York Heart Association.
*Each patient was included once in our cohort; in case of a second CABG procedure during the inclusion period, only the ﬁrst procedure was considered.
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patient and procedural characteristics are presented in
Table 1.
Prognostic Performance of cTnT
Compared with the reference category of cTnT ≤200 ng/L,
we found a monotonous increase in ORs for MACCE and the
safety composite outcome with increasing levels of conven-
tional and hs-cTnT (P<0.001 for trend, Table 2). There was a
numerical decrease in the OR for conventional cTnT category
of >800 to 1200 ng/L, but this was likely attributable to
chance. Figure 2 presents the distribution of early cTnT levels
among study participants and the associated ﬁtted probabil-
ities of MACCE. The estimated probabilities of MACCE for
cTnT levels in increments of 200 ng/L are also presented in
Table S1. For conventional cTnT, estimated probabilities of
MACCE were 10.3% at 200 ng/L, 34.8% at 800 ng/L, and
49.2% at 1400 ng/L; for hs-cTnT, the probabilities were 3.5%,
30.8%, and 55.0%, respectively.
Corresponding results for the safety composite outcome
are presented in Figure S1 and Table S1. For conventional
cTnT, the predicted probabilities for the safety composite
outcome were 18.6% at 200 ng/L, 40.7% at 800 ng/L, and
51.2% at 1400 ng/L. For hs-cTnT, the probabilities were
6.0%, 37.2%, and 59.3%, respectively. Finally, log cTnT
remained independently associated with MACCE and the
safety composite outcome in multivariable regression models
that included log (logistic EuroSCORE) and need for inotropes
or vasopressors within the ﬁrst 6 hours after CABG
(Table S2).
The AUCs for the association with MACCE were 0.72 for
conventional cTnT (95% CI, 0.67–0.78) and 0.77 for hs-cTnT
(95% CI, 0.72–0.81). Likewise, the AUCs for the association
with the safety composite were 0.66 for conventional cTnT
(95% CI, 0.61–0.71) and 0.74 for hs-cTnT (95% CI, 0.69–0.78).
Using the EuroSCORE as reference, the addition of cTnT
increased the AUC, with larger increments for MACCE (0.11
and 0.21 for conventional and hs-cTnT, respectively) than for
the safety composite (0.05 and 0.14, respectively) (Table 3).
The addition of the need for inotropes or vasopressors did not
result in relevant increases in the AUC.
Cutoff Values for cTnT
Table 4 presents 292 tables and corresponding ﬁtted
sensitivity, speciﬁcity, positive and negative LR, and the ﬁtted
posttest probability after a positive test result in 200 ng/L
increments up to 1400 ng/L. At the prespeciﬁed cutoff of
800 ng/L, the positive LR to rule in MACCE was 7.30 for
conventional cTnT (95% CI, 6.64–8.03) and 6.83 for hs-cTnT
(95% CI, 5.98–7.81). Corresponding positive LRs to rule in a
safety composite event were 8.44 (95% CI, 7.86–9.06) and
7.00 (95% CI, 6.31–7.76), respectively, at this cutoff. The
negative LRs at these cutoffs were consistently >0.2.
Nomograms of the relationship between pretest and
posttest probabilities of MACCE (left panel) and safety
Table 2. Univariable ORs of MACCE and the Safety Composite by cTnT Categories
Interval, ng/L N
MACCE Safety Composite
Events OR (95% CI) P Value for Trend Events OR (95% CI) P Value for Trend
Conventional cTnT
≤200 415 22 1 (Reference) <0.001 52 1 (Reference) <0.001
>200–400 208 32 3.25 (1.83–5.75) 44 1.87 (1.20–2.91)
>400–600 72 16 5.10 (2.53–10.30) 20 2.68 (1.49–4.85)
>600–800 20 6 7.66 (2.68–21.84) 7 3.76 (1.43–9.85)
>800–1200 18 4 5.10 (1.55–16.80) 9 6.98 (2.65–18.39)
>1200 16 12 53.6 (16.0–179.8) 14 48.9 (10.8–221.2)
High-sensitivity cTnT
≤200 199 6 1 (Reference) <0.001 9 1 (Reference) <0.001
>200–400 443 32 2.50 (1.03–6.09) 52 2.81 (1.35–5.82)
>400–600 190 23 4.43 (1.76–11.1) 28 3.65 (1.67–7.96)
>600–800 68 14 8.34 (3.06–22.7) 19 8.19 (3.49–19.2)
>800–1200 45 20 25.7 (9.44–70.2) 23 22.1 (9.08–53.6)
>1200 28 19 67.9 (21.8–211.4) 22 77.4 (25.2–238.0)
A nonparametric test for trend was performed across all troponin categories for each comparison. CI indicates conﬁdence interval; cTnT, cardiac troponin T; MACCE, major adverse cardiac
or cerebrovascular event; and OR, odds ratio.
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composite (right panel) after a negative or positive test result
for different cutoffs of conventional cTnT and hs-cTnT are
presented in Figure 3. In our cohort of patients undergoing
isolated CABG, the average probability of MACCE in the
absence of any additional information was 12%. On the basis
of the bottom left nomogram in Figure 3, this pretest
probability translates into a posttest probability of 48%
after a positive test result deﬁned by hs-cTnT levels of
>800 ng/L (dashed red lines). For a hypothetical higher-risk
cohort from a different hospital with an average probability of
MACCE of 20%, an hs-cTnT of >800 ng/L will yield a posttest
probability of 63% (dashed blue lines). Posttest probabilities
will increase with increasing cTnT cutoffs. An hs-cTnT of
>14 ng/L observed for patients in the higher-risk cohort will
yield a posttest probability of 80%. Nomograms for the
safety composite outcome are presented on the right of
Figure 3. Calibration was good for the cutoff of 800 ng/L. The
probability of MACCE for cTnT values >800 ng/L was 37%
(95% CI, 16%–62%) in the development cohort10 compared
with a probability of 47% (95% CI, 30%–65%) for cTnT values
>800 ng/L in the validation cohort. Corresponding probabil-
ities of the safety composite were 65% (95% CI, 41%–85%) in
the development cohort and 68% (95% CI, 49%–83%) in the
validation cohort. Table S3 presents a comparison of
observed and predicted probabilities for cTnT and hs-cTnT in
the validation cohort, again with a high concordance.
Association Between cTnT >800 ng/L and
Clinical Outcomes
Table 5 presents a comparison of primary and secondary
composite outcomes and their individual components between
patientswithearly cTnT levels≤800ng/Landpatientswithearly
cTnT levels >800 ng/L. Patients with conventional cTnT and hs-
cTnT levels >800 ng/L at 9 hours postoperatively were more
likely to experience aMACCE (unadjusted OR, 7.5 [95% CI, 3.7–
15.3]; andunadjustedOR, 12.6 [95%CI, 7.5–21.2], respectively)
and the safety composite outcome (unadjusted OR, 10.1 [95%
CI, 4.8–21.2]; and unadjusted OR, 11.8 [95% CI, 7.1–19.7],
respectively) comparedwithpatientswith cTnT levels≤800 ng/
L (Table 5). With respect to individual components of MACCE,
patients with conventional and hs-cTnT levels >800 ng/L were
more likely to experience an MI compared with patients with
cTnT levels ≤800 ng/L (Table 5). The magnitude of the
association for death and stroke was larger for conventional
cTnT than hs-cTnT (Table 5). For stroke in particular, the
associationwith hs-cTnT>800 ng/Lwas unclear, with awideCI
that was compatible with both a clinically relevant positive and
negative association. In sensitivity analyses after exclusion of
MI from the safety composite outcome deﬁnition, cTnT levels
>800 ng/L continued to be associated with the safety
composite; the association was again more pronounced for
conventional cTnT (unadjusted OR, 5.7; 95% CI, 2.7–12.2) than
for hs-cTnT (unadjusted OR, 2.5; 95% CI, 1.2–5.0).
Preoperative cTnT and MACCE
Conventional cTnT and hs-cTnT were measured preoperatively
in 104 and 203 patients, respectively. The median preoperative
conventional cTnT was 100 ng/L (IQR, 100–230 ng/L), and the
median preoperative hs-cTnT was 150 ng/mL (IQR, 70–400
ng/L). Preoperative conventional cTnT and hs-cTnT were not
signiﬁcantly associated with MACCE (OR, 1.26 [95% CI, 0.87–
1.82] for conventional cTnT; OR, 1.00 [95% CI, 0.76–1.31] for
hs-cTnT). Adjustment for preoperative cTnT increased the
association of early postoperative cTnT with MACCE (Table S4).
Discussion
This study provides a detailed analysis of the prognostic
importance of early postoperative cTnT measured between 6
Figure 2. Distribution of early cardiac troponin T (cTnT) and
probability of major adverse cardiac or cerebrovascular events
(MACCE). Risk of in-house MACCE; shaded region represents the
distribution of conventional or high-sensitivity troponin T mea-
sured 9 hours after coronary artery bypass grafting surgery. The
corresponding ﬁgures for the safety composite outcome are
shown in Figure S1.
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and 12 hours after isolated CABG to predict MACCE and a
safety composite outcome. The principal ﬁnding was that
early postoperative cTnT demonstrated moderate discrimina-
tion for MACCE (AUC, 0.72 for conventional cTnT and 0.77 for
hs-cTnT) and the safety composite outcome (AUC, 0.66 for
conventional cTnT and 0.74 for hs-cTnT). Second, a conven-
tional cTnT and hs-cTnT cutoff value of 800 ng/L provided
clinically relevant power (LR+ >5) to rule in MACCE and the
safety composite outcome. Accordingly, patients with early
conventional cTnT and hs-cTnT levels >800 ng/L were 7 to 12
times more likely to subsequently experience a MACCE or the
safety composite outcome in the hospital compared with
patients with early cTnT levels ≤800 ng/L.
Strengths and Limitations
The major strength of our study is its sample size. We
investigated a large and homogeneous group of consecutive
patients undergoing isolated CABG, and our study is larger
than previously published work on the prognostic importance
of early increases in TnI or cTnT.8,10 Another strength is that
we assessed the prognostic utility of conventional troponin
and high-sensitivity troponin, which have not been previously
examined. Finally, we constructed nomograms to allow
clinicians to derive posttest probabilities of the primary and
secondary outcomes in our study. This facilitates the clinical
translation of our work. However, our study has important
limitations. First, because there is no consensus about the
deﬁnition of periprocedural MI,17 the rate of periprocedural MI
largely varies depending on the deﬁnition used. We used a
well-established deﬁnition of periprocedural MI on the basis of
CK-MB measurements,12 which has also been used in
contemporary clinical trials in adults undergoing CABG.18
Second, all MIs in our study occurred <72 hours postoper-
atively, but we did not have details on the exact time of
diagnosis for every patient. Nevertheless, when we excluded
MI from the safety composite outcome in our sensitivity
analyses, there was still an association between cTnT and the
safety composite. Therefore, early cTnT appears not only to be
an early marker of periprocedural MI but also a useful marker
for other postoperative complications.
Context
Multiple studies have examined the association between post-
CABG changes in biomarkers and subsequent midterm or
long-term adverse events. With respect to CK-MB and TnI
measurements within 24 hours of CABG, the largest study
was an individual patient data meta-analysis of 7 cohorts and
including 18 908 patients. Small increments in CK-MB of 5 to
10 times the upper limit of normal were associated with 2.9
times increase in 30-day mortality (relative risk, 2.98; 95% CI,
1.53–5.80) compared with adults below the upper limit of
normal.19 For TnI, an increase of 40 to 100 times above the
upper limit of normal was the lowest threshold associated
with a signiﬁcantly increased risk of 30-day mortality in 2552
patients (relative risk, 3.6; 95% CI, 1.08–12.04) compared
with normal values.19 For conventional cTnT, 2 single-center
prospective cohort studies in 847 and 1350 patients
suggested considerably stronger associations with clinical
outcomes,1,20 although associations were expressed using
different metrics.
There has been less focus on the prognostic utility of early
troponin measurements to identify in-hospital complications
Table 3. Prognostic Accuracy of the Logistic EuroSCORE Alone and Combined With Prognostic Variables
Variable
MACCE Safety Composite
AUC (95% CI) IDI P Value AUC (95% CI) IDI P Value
Conventional cTnT
EuroSCORE 0.63 (0.57–0.69) Reference 0.66 (0.61–0.71) Reference
EuroSCORE+vasopressors 0.64 (0.59–0.70) 0.00 0.25 0.67 (0.62–0.71) 0.01 0.07
EuroSCORE+cTnT 0.74 (0.69–0.80) 0.09 0.00 0.71 (0.66–0.76) 0.06 0.00
EuroSCORE+cTnT+vasopressors 0.75 (0.70–0.80) 0.09 0.00 0.71 (0.67–0.76) 0.06 0.00
High-sensitivity cTnT
EuroSCORE 0.56 (0.50–0.61) Reference 0.61 (0.56–0.66) Reference
EuroSCORE+vasopressors 0.56 (0.51–0.62) 0.00 0.48 0.61 (0.56–0.66) 0.00 0.17
EuroSCORE+cTnT 0.77 (0.72–0.82) 0.14 0.00 0.75 (0.71–0.80) 0.13 0.00
EuroSCORE+cTnT+vasopressors 0.77 (0.72–0.82) 0.14 0.00 0.75 (0.71–0.80) 0.13 0.00
“Vasopressors” indicate the need for vasopressors or inotropes within the ﬁrst 6 hours after surgery. AUC indicates area under the receiver operating characteristic (curve); CI, conﬁdence
interval; cTnT, cardiac troponin T; IDI, integrated discrimination improvement; and MACCE, major adverse cardiac or cerebrovascular event.
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after CABG. These complications occur often immediately and
need emergent initiation of therapeutic measures to improve
the prognosis of patients. Apart from our pilot study in 290
patients, we are only aware of an analysis of 540 patients by
Eigel et al,8 which showed that an increase in TnI of 1 ng/L
measured immediately after completion of the surgical
intervention was associated with a 17-fold increase in the
odds of periprocedural MI or death after CABG. The same
group did not perform a comprehensive analysis of the
prognostic performance of troponin, and the analysis was
Table 4. Cutoff Points of cTnT
Cutoff, ng/L
No. of Operations
Sensitivity, % Speciﬁcity, % LR+ LR
Posttest
Probability, %TP FN TN FP
MACCE
Conventional cTnT
200 70 22 393 264 72 60 1.78 0.48 19
400 38 54 569 88 42 87 3.34 0.66 31
600 22 70 625 32 28 94 5.03 0.76 41
800 16 76 639 18 19 97 7.30 0.84 50
1000 12 80 648 9 13 99 9.74 0.88 57
1200 12 80 653 4 10 99 12.81 0.91 64
1400 9 83 654 3 7 100 15.52 0.93 68
High-sensitivity cTnT
200 108 6 193 666 95 22 1.21 0.22 14
400 76 38 604 255 68 71 2.33 0.45 24
600 53 61 771 88 43 89 4.11 0.63 36
800 39 75 825 34 26 96 6.83 0.77 48
1000 26 88 843 16 18 98 9.89 0.84 57
1200 19 95 850 9 13 99 12.75 0.88 63
1400 11 103 854 5 10 99 15.40 0.90 68
Safety composite
Conventional cTnT
200 94 52 363 240 62 60 1.57 0.62 25
400 50 96 527 76 35 88 3.06 0.73 39
600 30 116 579 24 23 95 5.03 0.80 51
800 23 123 592 11 15 98 8.44 0.87 64
1000 15 131 597 6 10 99 12.70 0.90 73
1200 14 132 601 2 7 100 19.27 0.93 80
1400 11 135 602 1 5 100 26.28 0.95 85
High-sensitivity cTnT
200 144 9 190 630 93 22 1.19 0.34 20
400 92 61 581 239 63 72 2.22 0.52 32
600 64 89 743 77 40 90 4.01 0.67 46
800 45 108 792 28 24 97 7.00 0.79 60
1000 29 124 807 13 16 98 10.59 0.85 69
1200 22 131 814 6 11 99 15.32 0.90 76
1400 13 140 817 3 8 100 20.55 0.92 81
Sensitivity, speciﬁcity, and posttest probability are ﬁtted. Fitted posttest probability of a positive test corresponds to the positive predictive value. cTnT indicates cardiac troponin T; FN,
false negative; FP, false positive; LR+, ﬁtted positive likelihood ratio that corresponds to a troponin value above the cutoff; LR, ﬁtted negative likelihood ratio for a troponin value below or
equal to the cutoff; MACCE, major adverse cardiac or cerebrovascular event; TN, true negative; and TP, true positive.
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based on patients recruited between December 1998 and
January 2000. Since then, important changes have occurred
in the clinical characteristics and management of patients
who undergo CABG and there has been notable progress in
the development of cardiac biomarkers, including the more
widespread use of hs-cTnT.
In our study, MECC was used in all operations, which is not
the standard approach for CABG surgery. However, this is
unlikely to affect the generalizability of our study. First, in a
meta-analysis comparing MECC and ECC,21 MECC was
associated with only a small clinically irrelevant reduction of
postoperative peak cardiac TnI of 180 ng/L (95% CI, 250
to 120 ng/L). Second, there is no difference in the
incidence of MACCE up to 30 days between conventional
ECC and off-pump CABG,22,23 suggesting that the event rate
associated with MECC is likely comparable to conventional
ECC.
Preoperative cTnT was measured in a subset of adults
in our study, and there was no association between preop-
erative cTnT and MACCE. This is consistent with previously
published observational studies reporting no association of
preoperative cTnT with 30-day major adverse events after
CABG24 or with long-term death after general cardiac
surgery.25 These ﬁndings are contrasting with recently
published ﬁndings in the setting of percutaneous coronary
intervention, where preprocedural cTnT appears more strongly
associated with 1- and 3-year mortality than postprocedural
cTnT.26–29
Our study is a contemporary and detailed analysis of the
prognostic performance of conventional and hs-cTnT assessed
Figure 3. Nomograms of the relation between pretest and posttest probability of major adverse cardiac
or cerebrovascular events (MACCE) or the safety composite, by troponin levels. The curves are based on
pretest probabilities and ﬁtted likelihood ratios of cardiac troponin T (cTnT) cutoffs for the risk of MACCE
(left panels) and the safety composite (right panels) for conventional cTnT (top panels) and hs-cTnT (bottom
panels). Black dashed lines represent the relation between pretest and posttest probabilities, ruling out
future events by cTnT levels equal to or smaller than the cutoff on the basis of negative likelihood ratios;
black solid lines, the relation between pretest and posttest probabilities, ruling in future events by cTnT
levels larger than the cutoff on the basis of positive likelihood ratios. Red and blue lines relate to reading
examples described in the text.
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6 to 12 hours after CABG. We found that increments in early
cTnT above a cutoff value of 800 ng/L provided clinically
relevant power to rule in MACCE and the safety composite
outcome. The association between conventional and hs-cTnT
and the safety composite outcome was robust to the exclusion
of MI from the deﬁnition of the outcome. Therefore, the
increase in cTnT associated with an impending periprocedural
MI after CABG does not preclude the use of cTnT as a clinically
relevant marker of short-term in-hospital prognosis beyond
mere diagnosis of periprocedural MI.
Implications
Early cTnT elevations may allow for the emergent investigation
and management of postoperative complications in patients
undergoing CABG. For instance, adults with a high posttest
probability of MACCE may be readily investigated with
noninvasive imaging, such as bedside echocardiography, to
assess for signs of periprocedural MI. Echocardiographic
evidence of akinetic or hypokinetic myocardium may guide
decision making about surgical reexploration of grafts,
emergency coronary angiography, or use of an intra-aortic
balloon pump. Similarly, adults with a high posttest probability
of the composite safety outcome may warrant additional
monitoring in the intensive care unit or in an intermediate-
care facility to optimize treatment. Early initiation of these
interventions may have the potential to improve postoperative
outcomes. Given the potential for important and timely
interventions in patients undergoing CABG, a randomized
controlled trial may be warranted, in which patients are
Table 5. Adverse Events
Events
cTnT
≤800 g/L
cTnT
>800 g/L
Univariable OR
(95% CI) P Value
Conventional cTnT n=715 n=34
MACCE, as a composite of all-cause mortality,
myocardial infarction, or stroke
76 (11) 16 (47) 7.5 (3.7–15.3) <0.001
Safety composite of MACCE, acute kidney injury,
resuscitation, prolongation or readmission of ICU
stay, or vasopressors
123 (17) 23 (68) 10.1 (4.8–21.2) <0.001
Death 4 (1) 2 (6) 11.1 (2.0–62.9) 0.027
Myocardial infarction 63 (9) 15 (44) 8.2 (4.0–16.9) <0.001
Stroke 10 (1) 3 (9) 6.8 (1.8–26.0) 0.018
Resuscitation 2 (0) 2 (6) 22.8 (3.1–167.1) 0.011
Prolonged ICU stay >48 h 20 (3) 8 (24) 10.7 (4.3–26.5) <0.001
Readmission to ICU 20 (3) 1 (3) 1.1 (0.1–8.1) 1.00
Vasopressors >24 h after surgery 7 (1) 0 (0) 0.73 (0.04–13.1) 1.00
Acute kidney injury 23 (3) 4 (12) 4.0 (1.3–12.3) 0.030
High-sensitivity cTnT n=900 n=73
MACCE, as a composite of all-cause mortality,
myocardial infarction, or stroke
75 (8) 39 (53) 12.6 (7.5–21.2) <0.001
Safety composite of MACCE, acute kidney injury,
resuscitation, prolongation or readmission of ICU
stay, or vasopressors
108 (12) 45 (62) 11.8 (7.1–19.7) <0.001
Death 2 (0) 1 (1) 6.2 (0.6–69.6) 0.21
Myocardial infarction 59 (7) 39 (53) 16.4 (9.6–27.8) <0.001
Stroke 18 (2) 1 (1) 0.7 (0.1–5.2) 1.00
Resuscitation 3 (0) 3 (4) 13.1 (2.6–66.4) 0.006
Prolonged ICU stay >48 h 13 (1) 2 (3) 1.9 (0.4–8.7) 0.31
Readmission to ICU 29 (3) 7 (10) 3.2 (1.3–7.5) 0.014
Vasopressors >24 h after surgery 1 (0) 1 (1) 12.5 (0.8–202) 0.14
Acute kidney injury 9 (1) 2 (3) 2.8 (0.6–13.2) 0.20
Data are given as number (percentage) unless otherwise indicated. Vasopressors in the safety composite means need for vasopressors >24 hours after surgery. CI indicates conﬁdence
interval; cTnT, cardiac troponin T; ICU, intensive care unit; MACCE, major adverse cardiovascular or cerebrovascular event; and OR, odds ratio.
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assigned to the use or nonuse of early cTnT to guide clinical
management and to discern whether the use of early cTnT for
clinical decision making is associated with a lower incidence
of MACCE or other complications. Extending the use of early
cTnT measurements to patients undergoing other types of
cardiac surgery will also require further research on patterns
of cTnT elevations postoperatively.24,25,30,31
Conclusion
In conclusion, cTnT levels assessed after 6 to 12 hours after
CABG are clinically useful in identifying patients at increased
risk of MACCEs and other complications. A carefully
designed randomized trial is required to determine whether
measurement of early cTnT also may result in meaningful
changes in clinical practice and improvement in clinical
outcomes.
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Table S1. Estimated probabilities of MACCE and the safety composite for specific cTnT levels in 
increments of 200 ng/L, stratified by conventional versus high sensitivity cardiac Troponin T. 
 Risk of MACCE (95% CI)  Risk of Safety composite (95% CI) 
Cut-off 
(ng/L) 
Conventional High sensitivity   Conventional High sensitivity 
200 10.3 (8.1 to 12.9) 3.5 (2.4 to 5.1)  18.6 (15.9 to 21.7) 6.0 (4.4 to 8.1) 
400 19.7 (16.1 to 23.9) 11.3 (9.3 to 13.8)  28.3 (24.0 to 32.9) 16.3 (13.9 to 19.0) 
600 27.7 (22.0 to 34.3) 20.9 (17.4 to 24.8)  35.2 (29.0 to 41.8) 27.2 (23.2 to 31.5) 
800 34.8 (27.1 to 43.7) 30.8 (25.2 to 37.0)  40.7 (33.0 to 49.0) 37.2 (31.3 to 43.6) 
1000 40.6 (30.9 to 51.1) 40.0 (32.2 to 48.3)  45.1 (35.8 to 54.6) 45.9 (38.1 to 53.9) 
1200 45.0 (33.9 to 56.5) 48.1 (38.5 to 57.8)  48.2 (38.0 to 58.6) 53.2 (44.0 to 62.2) 
1400 49.2 (36.9 to 61.6) 55.0 (44.1 to 65.5)  51.2 (40.1 to 62.2) 59.3 (49.0 to 68.8) 
 
CI, confidence interval.  
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Table S2. Association of logistic EuroSCORE, cardiac Troponin T and need for vasopressors with 
MACCE and safety composite 
  MACCE 
  
Safety composite 
  OR (95% CI) OR (95% CI) 
    univariable multivariable   univariable multivariable 
Conventional Troponin T      
 Logistic EuroSCORE 2.3 (1.5 to 3.6) 1.6 (1.0 to 2.6)  3.1 (2.2 to 4.4) 2.5 (1.7 to 3.7) 
 Troponin T 6.1 (3.8 to 9.8) 5.3 (3.3 to 8.6)  3.7 (2.5 to 5.4) 3.1 (2.1 to 4.6) 
 Vasopressors  1.9 (1.2 to 3.0) 1.4 (0.8 to 2.4)  2.0 (1.3 to 2.9) 1.4 (0.9 to 2.2) 
High sensitivity Troponin T  
 Logistic EuroSCORE 1.4 (1.0 to 2.1) 1.2 (0.8 to 1.8)  2.1 (1.5 to 2.9) 1.9 (1.3 to 2.8) 
 Troponin T 8.1 (5.2 to 12.5) 7.9 (5.1 to 12.3)  6.7 (4.5 to 9.9) 6.5 (4.4 to 9.6) 
  Vasopressors  1.2 (0.8 to 1.9) 1.0 (0.6 to 1.5)   1.4 (1.0 to 2.0) 1.1 (0.7 to 1.6) 
 
OR: odds ratio; CI: confidence interval 
‘Vasopressors’ indicates the need for vasopressors or inotropes within the first 6 hours after surgery. 
Multivariable analysis included all 3 predictor variables. Odds ratios for logistic EuroSCORE and 
Troponin T are expressed per 2 standard deviations after log transformation and can be interpreted 
similar to the ORs of categorical variables. 
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Table S3. Comparison of observed and predicted probabilities. 
  Observed probability (95% CI)  Predicted probability (95% CI) 
    ≤ 800 ng/L >800 ng/L   ≤ 800 ng/L >800 ng/L 
MACCE      
 Conventional Troponin T 11 (8 to 13) 47 (30 to 65)  10 (4 to 52) 51 (33 to 64) 
 High sensitivity Troponin T 8 (7 to 10) 53 (41 to 65)  9 (5 to 43) 48 (35 to 59) 
Safety composite      
 Conventional Troponin T  17 (15 to 20) 68 (49 to 83)  17 (7 to 55) 67 (49 to 74) 
  High sensitivity Troponin T 12 (10 to 14) 62 (50 to 73)   13 (7 to 45) 57 (44 to 65) 
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Table S4. Association of pre- and post-operative cardiac Troponin T with MACCE.  
 
    OR (95% CI) P 
Conventional Troponin T   
 Pre-operative 1.26 (.874 to 1.82) 0.22 
 Early post-operative, crude 2.96 (2.23 to 3.95) <0.001 
 Early post-operative, adjusted* 3.32 (1.50 to 6.98) 0.003 
High sensitivity Troponin T   
 Pre-operative 1.00 (.763 to 1.31) 1.00 
 Early post-operative, crude 5.79 (4.02 to 8.33) <0.001 
  Early post-operative, adjusted* 7.78 (3.62 to 16.7) <0.001 
 
*For pre-operative cTnT  
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Figure S1. Distribution of early cardiac Troponin T and probability of safety composite. 
  
Risk of in-house safety composite, shaded region represents the distribution of conventional 
or high sensitivity cTnT, respectively, measured 9 hours after CABG surgery.  
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